Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

valaciclovir

ApprovedSmall molecule

valaciclovir is one of 166 small molecule programs targeting Glioma. It is currently in Approved.

7

Indications

14

Total Trials

1

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

ChickenpoxActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

CognitionActive, not recruiting

Genital HerpesActive, not recruiting

ANCA-Associated VasculitisActive, not recruiting

Herpes ZosterActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

ChickenpoxPreclinical

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

CognitionPhase 2

Active, not recruiting

Genital HerpesApproved

Active, not recruiting

ANCA-Associated VasculitisPhase 2

Active, not recruiting

Herpes ZosterPhase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

valaciclovir

Veramyst

Flovent

Spiriva

Boehringer Ingelheim

Aclidinium Bromide

Zoloft

VViatris Specialty LLC

Narcan

Coumadin

Antibiotic

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

Phase 1/2Not yet recruiting

Glioma

NCT07346144

Clinical

Trials by Indication[1]

Herpes Simplex Virus3 trials

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Completed· GSK logo

GSK·Phase 4·NCT00116844·73 enrolled

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

Completed·HHeidelberg ImmunoTherapeutics GmbH·Phase 2·NCT04165122·122 enrolled

Valaciclovir to Prevent Transmission of Herpes Simplex Virus

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001649·180 enrolled

Herpes Zoster2 trials

Phase III Study of ASP2151 in Herpes Zoster Patients

Completed·MMaruho Co., Ltd.·Phase 3·NCT01959841·751 enrolled

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

Unknown status·AaRigen Pharmaceuticals, Inc.·Phase 2·NCT00652184·300 enrolled

Interaction1 trial

Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02226978·29 enrolled

Children1 trial

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Completed· GSK logo

GSK·Phase 1·NCT00297206·36 enrolled

Glioma1 trial

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Not yet recruiting·TTrogenix ltd·Phase 1/2·NCT07346144·68 enrolled

6 more indications

Genital Herpes1 trial

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

Completed· GSK logo

GSK·Phase 4·NCT00158860·384 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial

Terminated·BBelfast Health and Social Care Trust·Phase 2·NCT03699904·85 enrolled

Cognition1 trial

To Rescue Cognition With Valaciclovir

Completed·UUniversity Medical Center Groningen·Phase 2·NCT01364792·24 enrolled

ANCA-Associated Vasculitis1 trial

CMV Modulation of the Immune System in ANCA-associated Vasculitis

Unknown status·PProfessor Lorraine Harper·Phase 2·NCT01633476·38 enrolled

Chickenpox1 trial

Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)

Completed· GSK logo

GSK··NCT01390857·379 enrolled

Early Alzheimer's Disease1 trial

Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

Completed·HHugo Lovheim·Phase 2·NCT02997982·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for valaciclovir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — valaciclovir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for valaciclovir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Related News